Literature DB >> 10708721

P2X receptors counteract the vasodilatory effects of endothelium derived hyperpolarising factor.

M Malmsjö1, L Edvinsson, D Erlinge.   

Abstract

Dilatory responses of extracellular nucleotides were examined in the precontracted isolated rat mesenteric artery. Dilatation mediated by endothelium-derived hyperpolarising factor (EDHF) was studied in the presence of Nomega-nitro-L-arginine (L-NOARG) and indomethacin, and was most potently induced by the selective P2Y(1) receptor agonist adenosine 5'-O-thiodiphosphate (ADPbetaS), while 2-methylthioadenosine triphosphate (2-MeSATP) and adenosine triphosphate (ATP) were almost inactive. However, after P2X receptor desensitisation (with alphabeta-methylene-adenosine triphosphate, alphabeta-MeATP), 2-MeSATP and ATP potently stimulated EDHF-mediated dilatation. This can be explained by simultaneous activation of endothelial P2Y receptors that release EDHF, and depolarising P2X receptors on smooth muscle cells. Uridine triphosphate (UTP) also induced potent dilatation, suggesting EDHF release via P2Y(2)/P2Y(4) receptors. Uridine diphosphate (UDP) had only minor dilatory effects, and when pretreated with hexokinase it was almost inactive, suggesting a minor role for P2Y(6) receptors. The nitric oxide (NO) mediated dilatation was studied in the presence of charybdotoxin, apamin and indomethacin. ADPbetaS, 2-MeSATP, ATP and UTP were all potent relaxant agonists suggesting NO release via P2Y(1) and P2Y(2)/P2Y(4) receptors, while UDP was much less potent and efficacious. P2X receptor desensitisation had only minor effect on the NO-mediated dilatations. In conclusion, both EDHF and NO-mediated dilatation can be induced by activation of P2Y(1) and P2Y(2)/P2Y(4) receptors. P2X receptor stimulation of smooth muscle cells selectively counteracts the dilatory effect of EDHF.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10708721     DOI: 10.1016/s0014-2999(00)00010-8

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

Review 1.  Dinucleoside polyphosphates: strong endogenous agonists of the purinergic system.

Authors:  Vera Jankowski; Markus van der Giet; Harald Mischak; Michael Morgan; Walter Zidek; Joachim Jankowski
Journal:  Br J Pharmacol       Date:  2009-06-25       Impact factor: 8.739

Review 2.  The role of purinergic signaling in the liver and in transplantation: effects of extracellular nucleotides on hepatic graft vascular injury, rejection and metabolism.

Authors:  Guido Beldi; Keiichi Enjyoji; Yan Wu; Lindsay Miller; Yara Banz; Xiaofeng Sun; Simon C Robson
Journal:  Front Biosci       Date:  2008-01-01

3.  Spreading dilatation to luminal perfusion of ATP and UTP in rat isolated small mesenteric arteries.

Authors:  Polly Winter; Kim A Dora
Journal:  J Physiol       Date:  2007-05-03       Impact factor: 5.182

4.  Endothelium-dependent relaxation and endothelial hyperpolarization by P2Y receptor agonists in rat-isolated mesenteric artery.

Authors:  Hammit Mistry; Jonathan M Gitlin; Jane A Mitchell; C Robin Hiley
Journal:  Br J Pharmacol       Date:  2003-06       Impact factor: 8.739

5.  Desensitization of endothelial P2Y1 receptors by PKC-dependent mechanisms in pressurized rat small mesenteric arteries.

Authors:  R Rodríguez-Rodríguez; P Yarova; P Winter; K A Dora
Journal:  Br J Pharmacol       Date:  2009-10-20       Impact factor: 8.739

6.  ATP-induced vasodilation in human skeletal muscle.

Authors:  E E M van Ginneken; P Meijer; N Verkaik; P Smits; G A Rongen
Journal:  Br J Pharmacol       Date:  2004-02-09       Impact factor: 8.739

7.  Purinergic receptors in the splanchnic circulation.

Authors:  Manuela Morato; Teresa Sousa; António Albino-Teixeira
Journal:  Purinergic Signal       Date:  2008-04-29       Impact factor: 3.765

8.  Attenuated purinergic receptor function in patients with type 2 diabetes.

Authors:  Pia Thaning; Laurids T Bune; Ylva Hellsten; Henriette Pilegaard; Bengt Saltin; Jaya B Rosenmeier
Journal:  Diabetes       Date:  2009-10-06       Impact factor: 9.461

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.